Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
1.16
+0.04 (4.02%)
Real-time:   1:18PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.14 - 1.20
52 week 0.80 - 1.91
Open 1.15
Vol / Avg. 2.34M/1.81M
Mkt cap 807.82M
P/E     -
Div/yield     -
EPS -0.22
Shares 724.36M
Beta 1.84
Inst. own 96%
May 6, 2015
Q1 2015 Lexicon Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 23, 2015
Lexicon Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Mar 4, 2015
Q4 2014 Lexicon Pharmaceuticals Inc Earnings Call
Mar 4, 2015
Q4 2014 Lexicon Pharmaceuticals Inc Earnings Release
Mar 3, 2015
Lexicon Pharmaceuticals Inc at Cowen Health Care Conference
Feb 10, 2015
Lexicon Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 14, 2015
Lexicon Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 10, 2014
Lexicon Pharmaceuticals Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9665.39% -4686.14%
Operating margin -9626.73% -4607.16%
EBITD margin - -4478.31%
Return on average assets -78.93% -32.24%
Return on average equity -167.04% -47.67%
Employees 149 -
CDP Score - -

Address

8800 Technology Forest Pl
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development of breakthroughs treatments for human disease. The Company is presently into the development of two drug candidates. It is developing LX4211, an orally-delivered small molecule drug candidate, as a treatment for type1 and type2 diabetes. It has completed two Phase II clinical trials of LX4211 in type2 diabetes patients and a clinical trial of LX4211 in type2 diabetes patients. It is presently preparing for the initiation of pivotal Phase III clinical trials of LX4211 in type2 diabetes patients. The Company is also presently completing a Phase II clinical trial of LX4211 in type1 diabetes patients. It is also developing telotristat etiprate (LX1032), an orally-delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is presently conducting a pivotal Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Lonnel Coats President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate Development
Age: 49
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President - Clinical Development, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - Pharmaceutical Research
Age: 60
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 54
Bio & Compensation  - Reuters
Philippe J. Amouyal Independent Director
Age: 55
Bio & Compensation  - Reuters
Samuel L. Barker Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Robert J. Lefkowitz M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Alan S. Nies M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters